PhaseBio Pharmaceuticals Inc
OTC:PHASQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Winton Land Ltd
NZX:WIN
|
NZ |
|
Convano Inc
TSE:6574
|
JP |
|
S
|
Shenzhen SEG Co Ltd
SZSE:000058
|
CN |
|
Najran Cement Company SJSC
SAU:3002
|
SA |
|
Guangdong Guanhao High-Tech Co Ltd
SSE:600433
|
CN |
|
I
|
Indian Oil Corporation Ltd
BSE:530965
|
IN |
|
Great Elm Group Inc
NASDAQ:GEG
|
US |
|
Airthings ASA
OSE:AIRX
|
NO |
|
Quidel Corp
NASDAQ:QDEL
|
US |
|
M
|
Majuba Hill Copper Corp
CNSX:JUBA
|
CA |
|
Infrastrutture Wireless Italiane SpA
MIL:INW
|
IT |
|
VAMA Industries Ltd
BSE:512175
|
IN |
|
Jinhui Liquor Co Ltd
SSE:603919
|
CN |
|
Human Holdings Co Ltd
TSE:2415
|
JP |
PhaseBio Pharmaceuticals Inc
Total Liabilities
PhaseBio Pharmaceuticals Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PhaseBio Pharmaceuticals Inc
OTC:PHASQ
|
Total Liabilities
$153.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$137.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$36.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$81.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$9.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
PhaseBio Pharmaceuticals Inc
Glance View
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
See Also
What is PhaseBio Pharmaceuticals Inc's Total Liabilities?
Total Liabilities
153.6m
USD
Based on the financial report for Dec 31, 2021, PhaseBio Pharmaceuticals Inc's Total Liabilities amounts to 153.6m USD.
What is PhaseBio Pharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 1Y
103%
Over the last year, the Total Liabilities growth was 103%.
